Hong Kong
· Delayed Price · Currency is HKD VISEN Pharmaceuticals Statistics
Total Valuation
HKG:2561 has a market cap or net worth of HKD 5.10 billion. The enterprise value is 4.84 billion.
| Market Cap | 5.10B |
| Enterprise Value | 4.84B |
Important Dates
| Earnings Date | n/a |
| Ex-Dividend Date | n/a |
Share Statistics
HKG:2561 has 113.93 million shares outstanding.
| Current Share Class | 113.93M |
| Shares Outstanding | 113.93M |
| Shares Change (YoY) | n/a |
| Shares Change (QoQ) | n/a |
| Owned by Insiders (%) | 4.39% |
| Owned by Institutions (%) | n/a |
| Float | 30.62M |
Valuation Ratios
| PE Ratio | n/a |
| Forward PE | n/a |
| PS Ratio | 41.36 |
| PB Ratio | 15.91 |
| P/TBV Ratio | 15.92 |
| P/FCF Ratio | n/a |
| P/OCF Ratio | n/a |
| PEG Ratio | n/a |
Enterprise Valuation
| EV / Earnings | -25.59 |
| EV / Sales | 39.21 |
| EV / EBITDA | n/a |
| EV / EBIT | n/a |
| EV / FCF | -20.01 |
Financial Position
The company has a current ratio of 5.52, with a Debt / Equity ratio of 0.01.
| Current Ratio | 5.52 |
| Quick Ratio | 5.03 |
| Debt / Equity | 0.01 |
| Debt / EBITDA | n/a |
| Debt / FCF | -0.01 |
| Interest Coverage | -239.23 |
Financial Efficiency
| Return on Equity (ROE) | n/a |
| Return on Assets (ROA) | n/a |
| Return on Invested Capital (ROIC) | n/a |
| Return on Capital Employed (ROCE) | -16.32% |
| Revenue Per Employee | n/a |
| Profits Per Employee | n/a |
| Employee Count | n/a |
| Asset Turnover | n/a |
| Inventory Turnover | n/a |
Taxes
| Income Tax | n/a |
| Effective Tax Rate | n/a |
Stock Price Statistics
| Beta (5Y) | n/a |
| 52-Week Price Change | n/a |
| 50-Day Moving Average | n/a |
| 200-Day Moving Average | n/a |
| Relative Strength Index (RSI) | 40.88 |
| Average Volume (20 Days) | 40,075 |
Short Selling Information
| Short Interest | n/a |
| Short Previous Month | n/a |
| Short % of Shares Out | n/a |
| Short % of Float | n/a |
| Short Ratio (days to cover) | n/a |
Income Statement
In the last 12 months, HKG:2561 had revenue of HKD 123.40 million and -189.10 million in losses. Loss per share was -20.24.
| Revenue | 123.40M |
| Gross Profit | 123.40M |
| Operating Income | -52.46M |
| Pretax Income | -189.10M |
| Net Income | -189.10M |
| EBITDA | -51.48M |
| EBIT | -52.46M |
| Loss Per Share | -20.24 |
Balance Sheet
The company has 268.76 million in cash and 3.31 million in debt, giving a net cash position of 265.45 million or 2.33 per share.
| Cash & Cash Equivalents | 268.76M |
| Total Debt | 3.31M |
| Net Cash | 265.45M |
| Net Cash Per Share | 2.33 |
| Equity (Book Value) | 320.77M |
| Book Value Per Share | 34.34 |
| Working Capital | 243.92M |
Cash Flow
In the last 12 months, operating cash flow was -241.44 million and capital expenditures -320,104, giving a free cash flow of -241.76 million.
| Operating Cash Flow | -241.44M |
| Capital Expenditures | -320,104 |
| Free Cash Flow | -241.76M |
| FCF Per Share | -2.12 |
Margins
Gross margin is 100.00%, with operating and profit margins of -42.51% and -153.23%.
| Gross Margin | 100.00% |
| Operating Margin | -42.51% |
| Pretax Margin | -153.23% |
| Profit Margin | -153.23% |
| EBITDA Margin | -41.72% |
| EBIT Margin | -42.51% |
| FCF Margin | n/a |
Dividends & Yields
HKG:2561 does not appear to pay any dividends at this time.
| Dividend Per Share | n/a |
| Dividend Yield | n/a |
| Dividend Growth (YoY) | n/a |
| Years of Dividend Growth | n/a |
| Payout Ratio | n/a |
| Buyback Yield | n/a |
| Shareholder Yield | n/a |
| Earnings Yield | -3.70% |
| FCF Yield | -4.74% |
Stock Splits
This stock does not have any record of stock splits.
| Last Split Date | n/a |
| Split Type | n/a |
| Split Ratio | n/a |
Scores
HKG:2561 has an Altman Z-Score of -5.8. A Z-score under 3 suggests an increased risk of bankruptcy.
| Altman Z-Score | -5.8 |
| Piotroski F-Score | n/a |